Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner.

Jo SH, Ren R.

J Biol Chem. 2012 Jan 13;287(3):1770-8. doi: 10.1074/jbc.M111.289728. Epub 2011 Nov 22.

2.

IRF-4 functions as a tumor suppressor in early B-cell development.

Acquaviva J, Chen X, Ren R.

Blood. 2008 Nov 1;112(9):3798-806. doi: 10.1182/blood-2007-10-117838. Epub 2008 Aug 19.

3.

Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.

Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI.

J Biol Chem. 2014 May 30;289(22):15642-52. doi: 10.1074/jbc.M113.544320. Epub 2014 Apr 21.

4.

The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.

Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, Kostenko EV, Ozer HL, Whitehead IP.

Oncogene. 2008 Mar 27;27(14):2064-71. Epub 2007 Oct 8.

5.

Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.

Jo SH, Schatz JH, Acquaviva J, Singh H, Ren R.

Blood. 2010 Oct 14;116(15):2759-67. doi: 10.1182/blood-2009-07-234559. Epub 2010 Jun 28.

6.

ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.

Tamura T, Kong HJ, Tunyaplin C, Tsujimura H, Calame K, Ozato K.

Blood. 2003 Dec 15;102(13):4547-54. Epub 2003 Aug 21.

7.

Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells.

Dror N, Rave-Harel N, Burchert A, Azriel A, Tamura T, Tailor P, Neubauer A, Ozato K, Levi BZ.

J Biol Chem. 2007 Feb 23;282(8):5633-40. Epub 2006 Dec 22.

8.

PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.

Peng C, Chen Y, Yang Z, Zhang H, Osterby L, Rosmarin AG, Li S.

Blood. 2010 Jan 21;115(3):626-35. doi: 10.1182/blood-2009-06-228130. Epub 2009 Nov 18.

9.

Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription.

Huang W, Zhou W, Saberwal G, Konieczna I, Horvath E, Katsoulidis E, Platanias LC, Eklund EA.

Mol Cell Biol. 2010 Oct;30(19):4575-94. doi: 10.1128/MCB.01595-09. Epub 2010 Aug 2.

10.

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Koschmieder S, Gƶttgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, Dayaram T, Geary K, Green AR, Tenen DG, Huettner CS.

Blood. 2005 Jan 1;105(1):324-34. Epub 2004 Aug 26.

11.

PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S, Lucas DM, Jacob ST.

J Biol Chem. 2009 Jan 2;284(1):455-64. doi: 10.1074/jbc.M802840200. Epub 2008 Nov 7.

12.

KLF4 suppresses transformation of pre-B cells by ABL oncogenes.

Kharas MG, Yusuf I, Scarfone VM, Yang VW, Segre JA, Huettner CS, Fruman DA.

Blood. 2007 Jan 15;109(2):747-55. Epub 2006 Sep 5.

14.

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.

He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, Choi JK, Ren R, Pear WS.

Blood. 2002 Apr 15;99(8):2957-68.

15.

CRKL binding to BCR-ABL and BCR-ABL transformation.

Kolibaba KS, Bhat A, Heaney C, Oda T, Druker BJ.

Leuk Lymphoma. 1999 Mar;33(1-2):119-26.

PMID:
10194128
16.

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B.

EMBO J. 1997 Oct 15;16(20):6151-61.

17.

A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.

Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ.

Cancer Res. 2010 Sep 15;70(18):7325-35. doi: 10.1158/0008-5472.CAN-10-0607. Epub 2010 Aug 31.

18.

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW.

Mol Cell Biol. 2006 Aug;26(16):6082-93.

19.

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.

Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D.

Blood. 2008 Jan 15;111(2):816-28. Epub 2007 Oct 9.

Supplemental Content

Support Center